LV10051A - How to get lyophilisate ifosfamida - Google Patents
How to get lyophilisate ifosfamidaInfo
- Publication number
- LV10051A LV10051A LV920174A LV920174A LV10051A LV 10051 A LV10051 A LV 10051A LV 920174 A LV920174 A LV 920174A LV 920174 A LV920174 A LV 920174A LV 10051 A LV10051 A LV 10051A
- Authority
- LV
- Latvia
- Prior art keywords
- ifosfamida
- lyophilisate
- ifosfamide
- weight
- hexitol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
1. A lyophilized preparation consisting of ifosfamide and 0.1 to 17 parts by weight hexitol per part by weight ifosfamide and, optionally, other standard pharmaceutical auxiliaries.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE3637089 | 1986-10-31 |
Publications (2)
Publication Number | Publication Date |
---|---|
LV10051A true LV10051A (en) | 1994-05-10 |
LV10051B LV10051B (en) | 1995-06-20 |
Family
ID=6312873
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LVP-92-174A LV10051B (en) | 1986-10-31 | 1992-10-27 | Method for producing of lyophilized yphosphamide |
Country Status (25)
Country | Link |
---|---|
EP (1) | EP0265812B1 (en) |
JP (1) | JPS63159319A (en) |
KR (1) | KR900003491B1 (en) |
AT (1) | ATE55250T1 (en) |
AU (1) | AU598602B2 (en) |
CA (1) | CA1314231C (en) |
DD (1) | DD262582A5 (en) |
DE (1) | DE3764235D1 (en) |
DK (1) | DK169308B1 (en) |
EG (1) | EG18333A (en) |
ES (1) | ES2017982B3 (en) |
FI (1) | FI87140C (en) |
GE (1) | GEP19971025B (en) |
GR (1) | GR3000708T3 (en) |
HU (1) | HU197987B (en) |
IL (1) | IL84312A (en) |
IN (1) | IN168119B (en) |
LV (1) | LV10051B (en) |
MX (1) | MX8958A (en) |
NO (1) | NO873860L (en) |
PT (1) | PT86032B (en) |
RU (1) | RU1836079C (en) |
UA (1) | UA11075A (en) |
YU (1) | YU197387A (en) |
ZA (1) | ZA878183B (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE65402T1 (en) * | 1988-03-19 | 1991-08-15 | Asta Pharma Ag | IFOSFAMIDE MESNA LYOPHILISATE AND PROCESS FOR PRODUCTION THEREOF. |
US5227373A (en) * | 1991-10-23 | 1993-07-13 | Bristol-Myers Squibb Co. | Lyophilized ifosfamide compositions |
WO1995007083A1 (en) * | 1993-09-10 | 1995-03-16 | F.H. Faulding & Co. Limited | Ifosfamide lyophilisate composition |
DE19529057B4 (en) * | 1995-08-08 | 2007-12-13 | Baxter Healthcare S.A. | Ifosfamide lyophilizate preparations |
WO1999044604A1 (en) * | 1998-03-03 | 1999-09-10 | Shionogi & Co., Ltd. | Pharmaceutical compositions containing the phospholipase inhibitor sodium [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl)-1h-indol-4-yl]oxy]acetate |
AU2003276689B2 (en) * | 2002-09-05 | 2009-04-09 | Bharat Serums And Vaccines Ltd. | Liquid stable composition of oxazaphosphorine with mesna |
ES2342380T3 (en) * | 2002-12-02 | 2010-07-06 | BHARAT SERUMS & VACCINES LTD. | IFOSFAMIDE COMPOSITIONS FOR PARENTERAL ADMINISTRATION AND A PROCEDURE FOR PREPARATION. |
US8436190B2 (en) * | 2005-01-14 | 2013-05-07 | Cephalon, Inc. | Bendamustine pharmaceutical compositions |
DK2071917T3 (en) * | 2006-09-29 | 2013-03-04 | Infa Sa | Packaging system for pharmaceutical compositions and kits for intravenous administration |
WO2016087001A1 (en) * | 2014-12-04 | 2016-06-09 | Huawei Technologies Co., Ltd. | Load allocation in a data communication network |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3732340A (en) * | 1966-07-11 | 1973-05-08 | Asta Werke Ag Chem Fab | N',o-propylene phosphoric acid ester diamides |
DE2750207A1 (en) * | 1977-05-09 | 1978-11-16 | Walton J Smith | Anhydrous compsn. prodn. by freeze drying hydrated, hydrolysable prod. - esp. aspirin or aspirin salt solns. |
DE3279834D1 (en) * | 1981-12-31 | 1989-08-31 | Asta Pharma Ag | 4-sulfido-oxaza phosphorines and their use in the treatment of cancer, and in immunosuppression |
US4537883A (en) * | 1982-11-12 | 1985-08-27 | Mead Johnson & Company | Lyophilized cyclophosphamide |
-
1987
- 1987-09-15 NO NO873860A patent/NO873860L/en unknown
- 1987-10-20 DE DE8787115322T patent/DE3764235D1/en not_active Expired - Lifetime
- 1987-10-20 EP EP87115322A patent/EP0265812B1/en not_active Expired - Lifetime
- 1987-10-20 AT AT87115322T patent/ATE55250T1/en not_active IP Right Cessation
- 1987-10-20 ES ES87115322T patent/ES2017982B3/en not_active Expired - Lifetime
- 1987-10-23 MX MX895887A patent/MX8958A/en unknown
- 1987-10-26 IN IN837/CAL/87A patent/IN168119B/en unknown
- 1987-10-27 FI FI874727A patent/FI87140C/en not_active IP Right Cessation
- 1987-10-28 EG EG61687A patent/EG18333A/en active
- 1987-10-29 RU SU874203570A patent/RU1836079C/en active
- 1987-10-29 JP JP62272002A patent/JPS63159319A/en active Granted
- 1987-10-29 UA UA4203570A patent/UA11075A/en unknown
- 1987-10-29 PT PT86032A patent/PT86032B/en unknown
- 1987-10-29 IL IL84312A patent/IL84312A/en not_active IP Right Cessation
- 1987-10-30 ZA ZA878183A patent/ZA878183B/en unknown
- 1987-10-30 KR KR1019870012077A patent/KR900003491B1/en not_active IP Right Cessation
- 1987-10-30 CA CA000550706A patent/CA1314231C/en not_active Expired - Lifetime
- 1987-10-30 DD DD87308471A patent/DD262582A5/en not_active IP Right Cessation
- 1987-10-30 DK DK569687A patent/DK169308B1/en not_active IP Right Cessation
- 1987-10-30 YU YU01973/87A patent/YU197387A/en unknown
- 1987-10-30 HU HU874900A patent/HU197987B/en unknown
- 1987-10-30 AU AU80529/87A patent/AU598602B2/en not_active Ceased
-
1990
- 1990-08-09 GR GR90400533T patent/GR3000708T3/en unknown
-
1992
- 1992-10-27 LV LVP-92-174A patent/LV10051B/en unknown
-
1993
- 1993-07-07 GE GEAP1993972A patent/GEP19971025B/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI891283A0 (en) | IFOSFAMID-MESNA-LYOFILISAT AND FOERFARANDE FOER DESS FRAMSTAELLNING. | |
DE3855451D1 (en) | Substituted 1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs | |
DK275488D0 (en) | indolone derivatives | |
ATE66143T1 (en) | SLOW RELEASE SOLID PREPARATION. | |
GR890100838A (en) | A novel therapeutic active compound and preparation method therefore. | |
DE3766200D1 (en) | L-DOPA CONTAINING MEDICINAL PRODUCT. | |
PH23565A (en) | Novel pyrimidinylpyrimidine derivatives and a plant disease protectant containing them as the active ingredient | |
LV10051A (en) | How to get lyophilisate ifosfamida | |
IT1212143B (en) | COMPOSITION WITH TRICHOGENIC ACTIVITY. | |
DK23490A (en) | IMPLANTED ANTIBIOTIC PREPARATION WITH REGULATED RELEASE | |
FR2603284B1 (en) | 7-OXABICYCLO ACID DERIVATIVES (2.2.1.) HYDROXAMIC HEPTANE WITH THERAPEUTIC ACTION | |
KR900700484A (en) | Aminopropanol derivative of 1,4: 3,6-dianhydro hexitol salate, its preparation and use as a medicament | |
DE3773322D1 (en) | PHARMACEUTICAL PREPARATIONS WITH HEALING ACTIVITY. | |
IT213056Z2 (en) | TIPS TO ASSEMBLE THE OPENERS ON AGRICULTURAL TRACTORS WITHOUT AFFECTING THE NECESSARY MECHANICAL STRENGTH OF THE SET |